EyePoint, Inc. (EYPT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.40-5.51%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge EyePoint, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	301,077
EPS	—	-0.702
Annual ending 2026-12-31
Revenue	—	1.67M
EPS	—	-3.632
Annual ending 2027-12-31
Revenue	—	7.29M
EPS	—	-2.219

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve full enrollment by Q3 2026	The company targets full enrollment in clinical trials by Q3 2026.	Intact	Enrollment falls short of full target by Q3 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Fully fund Phase 3 pivotal DME program	It aims to fully fund the Phase 3 DME program.	Under Pressure	Failure to secure full funding for Phase 3 DME program in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance Phase 3 wet AMD program	EyePoint is advancing its Phase 3 wet AMD program.	Under Pressure	Failure to meet key Phase 3 milestones in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.22

$-2.93 → $-2.22 · observed estimates

FY2027 revenue$0.01B

$0.04B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.93	$40,605,099	8 / 9
2026-07-25	$-3.04	$32,756,770	12 / 14
2026-07-26	$-3.04	$32,756,770	12 / 14
2026-07-27	$-3.04	$32,756,770	12 / 14
2026-07-28	$-3.00	$32,747,956	9 / 9
2026-07-29	$-3.00	$32,747,956	9 / 9
2026-07-30	$-3.04	$32,756,770	12 / 14
2026-07-31	$-3.00	$32,747,956	9 / 9
2026-08-01	$-3.00	$32,747,956	9 / 9
2026-08-02	$-3.04	$32,756,770	12 / 14
2026-08-03	$-3.00	$32,747,956	9 / 9
2026-08-04	$-3.04	$32,756,770	12 / 14
2026-08-05	$-3.04	$32,756,770	12 / 14
2026-08-06	$-3.00	$32,747,956	9 / 9
2026-08-07	$-3.01	$29,467,528	9 / 9
2026-08-08	$-3.08	$41,620,430	12 / 11
2026-08-09	$-3.08	$41,620,430	12 / 11
2026-08-10	$-3.08	$41,620,430	12 / 11
2026-08-11	$-3.06	$31,972,850	12 / 11
2026-08-12	$-3.01	$29,467,528	9 / 9
2026-08-13	$-3.03	$17,190,800	12 / 10
2026-08-14	$-3.01	$29,467,528	9 / 9
2026-08-15	$-3.01	$29,467,528	9 / 9
2026-08-16	$-3.01	$29,467,528	9 / 9
2026-08-17	$-3.01	$29,467,528	9 / 9
2026-08-18	$-3.01	$29,467,528	9 / 9
2026-08-19	$-3.01	$29,467,528	9 / 9
2026-08-20	$-2.77	$17,921,913	9 / 9
2026-08-21	$-2.77	$17,921,913	8 / 8
2026-08-22	$-2.77	$17,921,913	9 / 9
2026-08-23	$-2.77	$17,921,913	9 / 9
2026-08-24	$-2.77	$17,921,913	9 / 9
2026-08-25	$-2.77	$17,921,913	9 / 9
2026-08-26	$-2.77	$17,921,913	9 / 9
2026-08-27	$-2.77	$17,921,913	9 / 9
2026-08-28	$-2.77	$17,921,913	9 / 9
2026-08-29	$-2.77	$17,921,913	9 / 9
2026-08-30	$-2.77	$17,921,913	9 / 9
2026-08-31	$-2.77	$17,921,913	9 / 9
2026-09-01	$-2.77	$17,921,913	9 / 9
2026-09-02	$-2.77	$17,921,913	9 / 9
2026-09-03	$-2.73	$17,921,913	9 / 9
2026-09-04	$-2.73	$17,921,913	9 / 9
2026-09-05	$-2.73	$17,921,913	9 / 9
2026-09-06	$-2.73	$17,921,913	9 / 9
2026-09-07	$-2.73	$17,921,913	9 / 9
2026-09-08	$-2.73	$17,921,913	9 / 9
2026-09-09	$-2.73	$17,921,913	9 / 9
2026-09-10	$-2.73	$17,921,913	9 / 9
2026-09-11	$-2.73	$17,921,913	9 / 9
2026-09-12	$-2.73	$17,921,913	9 / 9
2026-09-13	$-2.73	$17,921,913	9 / 9
2026-09-14	$-2.73	$17,921,913	9 / 9
2026-09-15	$-2.73	$17,925,760	9 / 9
2026-09-16	$-2.73	$17,925,760	9 / 9
2026-09-17	$-2.73	$17,925,760	9 / 9
2026-09-18	$-2.73	$17,925,760	9 / 9
2026-09-19	$-2.73	$17,925,760	9 / 9
2026-09-20	$-2.73	$17,925,760	9 / 9
2026-09-21	$-2.73	$17,925,760	9 / 9
2026-09-22	$-2.73	$17,925,760	9 / 9
2026-09-23	$-2.73	$17,925,760	9 / 9
2026-09-24	$-2.73	$17,925,760	9 / 9
2026-09-25	$-2.73	$17,925,760	9 / 9
2026-09-26	$-2.73	$17,925,760	9 / 9
2026-09-27	$-2.73	$17,925,760	9 / 9
2026-09-28	$-2.73	$17,925,760	9 / 9
2026-09-29	$-2.73	$17,925,760	9 / 9
2026-09-30	$-2.73	$17,925,760	9 / 9
2026-10-01	$-2.73	$17,925,760	9 / 9
2026-10-02	$-2.73	$17,925,760	9 / 9
2026-10-03	$-2.73	$17,925,760	9 / 9
2026-10-04	$-2.73	$17,925,760	9 / 9
2026-10-05	$-2.73	$17,925,760	9 / 9
2026-10-06	$-2.73	$17,925,760	9 / 9
2026-10-07	$-2.73	$17,925,760	9 / 9
2026-10-08	$-2.73	$17,925,760	9 / 9
2026-10-09	$-2.73	$17,925,760	9 / 9
2026-10-10	$-2.73	$17,925,760	9 / 9
2026-10-11	$-2.73	$17,925,760	9 / 9
2026-10-12	$-2.73	$17,925,760	9 / 9
2026-10-13	$-2.73	$17,925,760	9 / 9
2026-10-14	$-2.73	$17,925,760	9 / 9
2026-10-15	$-2.73	$17,925,760	9 / 9
2026-10-16	$-2.73	$17,925,760	9 / 9
2026-10-17	$-2.73	$17,925,760	9 / 9
2026-10-18	$-2.73	$17,925,760	9 / 9
2026-10-19	$-2.73	$17,925,760	9 / 9
2026-10-20	$-2.73	$17,925,760	9 / 9
2026-10-21	$-2.50	$7,310,882	10 / 12
2026-10-22	$-2.22	$7,287,805	10 / 12
2026-10-23	$-2.22	$7,287,805	10 / 12
2026-10-24	$-2.22	$7,287,805	10 / 12

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	13	0	0
2026-06-01	12	0	0
2026-07-01	14	0	0
2026-08-01	14	5	0
2026-09-01	8	6	0
2026-10-01	7	10	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 10 Hold · 1 Sell / Strong Sell

0 upgrades3 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 5 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 20 · prior Aug 18

$5.00 → $1.00-80.0%

Mizuho SecuritiesOct 20 · prior Jul 29

$39.00 → $0.50-98.7%

JefferiesOct 19 · prior Aug 17

$8.00 → $1.00-87.5%

$0$21.45$42.90

0 raises · 3 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve full enrollment by Q3 2026Direct metric needs a verified mapping
Fully fund Phase 3 pivotal DME programPublished status: Under Pressure
Advance Phase 3 wet AMD programPublished status: Under Pressure

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-97.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

EyePoint, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making development-stage biotech, not a proven earnings compounder. The long-term thesis is in a watch state: management continues to prioritize DURAVYU Phase 3 development in DME, but the evidence of execution remains limited.

What's priced into EyePoint, Inc.

The valuation signal says EYPT is cheap versus peers, but confidence in that comparison is low. The expectations gap is slightly negative, suggesting expectations are not especially demanding; however, that does not remove the risk from continued losses or execution setbacks.

What the fundamentals likely do

Near term, another earnings miss is a material risk after recent misses, and the overall risk label has risen to high. Management has announced workforce and cost reductions, but the expected savings are not yet reflected in reported results; cash and investments were estimated at $118 million at September 30, below the $180 million reported at June 30. Over the multi-year view, DURAVYU’s DME development remains active, but the evidence snapshot contains no new clinical outcome data.

What EyePoint, Inc. hinges on

The thesis hinges on progress in the DME program, delivery of cost savings, and whether cash runway can support development; management’s Q4 2027 runway estimate has not been updated in the October disclosure. Near-term outcomes also depend on the next guidance update and broader Healthcare-sector signals, while weakening employment data could add pressure to cyclical names.